89Bio, Inc. Stock Price, News & Analysis

89bio, Inc. (Nasdaq: ETNB) presented new data from the Phase 1b/2a study on pegozafermin for treating nonalcoholic steatohepatitis (NASH) at the AASLD Liver Meeting 2022. In a post-hoc analysis of cohort 7, it was found that excluding patients with fibrosis stage 4 (F4) improved histological response rates. Out of 19 patients, 6 were identified as F4. Key findings included a 77% response rate for ≥ 2 point reduction in NAS after excluding F4 patients. The company aims to report topline data from the Phase 2b ENLIVEN trial in Q1 2023, further evaluating pegozafermin's efficacy.

89bio, a clinical-stage biopharmaceutical company focusing on therapies for liver and cardio-metabolic diseases, will participate in the H.C. Wainwright 6th Annual NASH Investor Conference on October 17, 2022, at 11:30 AM ET.

Management will engage in a fireside chat and one-on-one investor meetings. The presentation will be available via webcast, accessible here.

89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright 24^th Annual Global Investment Conference on September 12, 2022, at 4:00 PM ET. The event includes a fireside chat and one-on-one investor meetings, accessible via webcast on the company's website. 89bio is focused on developing innovative therapies for liver and cardiometabolic diseases, particularly its lead candidate, pegozafermin, aimed at treating non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).

89bio, Inc. (Nasdaq: ETNB) presented positive results from the ENTRIGUE Phase 2 trial of pegozafermin for severe hypertriglyceridemia (SHTG) at the ESC Congress 2022. The treatment significantly reduced triglycerides (TG) across all doses, achieving median reductions of up to 63% compared to a 12% reduction in the placebo group. Pegozafermin also improved liver fat and glycemic control. The findings support advancing into a Phase 3 trial anticipated in the first half of 2023, indicating potential for pegozafermin as a key treatment for cardio-metabolic and liver diseases.

89bio, Inc. (Nasdaq: ETNB) has successfully completed enrollment in its Phase 2b ENLIVEN trial of pegozafermin, targeting non-alcoholic steatohepatitis (NASH). A total of 219 patients have been enrolled to receive either active treatment or placebo. Topline data is anticipated in the first quarter of 2023. The trial aims to evaluate the drug's efficacy and safety profile, building on previous positive results. The pegozafermin candidate utilizes innovative technology to enhance its therapeutic potential for patients suffering from liver diseases.

89bio, Inc. (Nasdaq: ETNB) announced positive topline results from the ENTRIGUE Phase 2 trial of pegozafermin for severe hypertriglyceridemia (SHTG) patients, with significant triglyceride reductions (up to 63%). The company plans to initiate a Phase 3 trial in the first half of 2023. They raised $94.5 million from a public offering, bolstering their financial position with a cash balance of approximately $200 million. However, R&D expenses increased to $19.7 million, and net loss widened to $25.1 million. Topline data from the ENLIVEN Phase 2b trial for NASH is anticipated in early 2023.

89bio, Inc. (Nasdaq: ETNB) announced the completion of its underwritten public offering, raising approximately $94.5 million. The offering included 18,675,466 shares of common stock and warrants for 9,337,733 shares, priced at $3.55 per share. Additionally, pre-funded warrants for 7,944,252 shares were issued at $3.549 each. Key institutional investors participated, including BVF Partners and Deep Track Capital. The offering is supported by a valid SEC registration statement effective since April 2021.

89bio, Inc. (Nasdaq: ETNB) announced the pricing of a public offering of 18,675,466 shares of common stock at $3.55 per share, along with warrants for 9,337,733 additional shares. The offering also includes pre-funded warrants for 7,944,252 shares at $3.549 each. The anticipated gross proceeds are approximately $94.5 million, expected to close around July 1, 2022. BofA Securities and SVB Securities are leading the offering. The securities are available through a filed shelf registration statement with the SEC.

On June 28, 2022, 89bio (Nasdaq: ETNB) announced a public offering of $75 million in common stock, including pre-funded warrants for select investors. The offering is contingent on market conditions and entails no guarantees regarding completion terms. Proceeds are earmarked for ongoing clinical development of pegozafermin and other corporate purposes. BofA Securities and SVB Securities are the book-running managers for this initiative. A registration statement has been filed with the SEC, allowing potential investors to access detailed offering information.